NASDAQ: AXSM

Axsome Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 12, 2022.

If you purchased Axsome securities between December 30, 2019 and April 22, 2022 and would like to join the action, please click “Join This Class Action.”

Class Period:December 30, 2019 through April 22, 2022

Deadline:

8 Days
If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that:

  • Axsome’s chemistry, manufacturing, and control (“CMC”) practices were deficient with respect to AXS-07 and its manufacturing process;
  • as a result, Axsome was unlikely to submit the AXS-07 New Drug Application (“NDA”) on its initially represented timeline;
  • the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration (“FDA”) reviewed the AXS-07 NDA;
  • accordingly, the FDA was unlikely to approve the AXS-07 NDA;
  • as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and
  • as a result, the Company’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:
Company Name: Axsome Therapeutics, Inc.
Stock Symbol: AXSM
Class Period: December 30, 2019 through April 22, 2022
Court: United States District Court for the Southern District of New York

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top